Metagenomi, Inc. Common Stock
MGX
NASDAQ·Healthcare·Biotechnology·Mkt cap $44.0M
$1.17
▲ +0.86%
P/E
—
Mkt Cap
$44.0M
52-Wk Range
$1.13–$3.95
52-Week Range
$1.13 - $3.95
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 37.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary metagenomics-derived genome editing toolbox
- Strategic partnerships with industry leaders (Moderna, Ionis, Affini-T)
- Diverse portfolio of cutting-edge editing technologies
- Strong intellectual property and patent protection
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Revenue decline expected
Expansion of in vivo human therapeutic applications with Moderna
Value
Valuation data unavailable
Momentum
Weak
-8.6% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying MGX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 10, 2026
AUG 10, 2026
Reported EPS of -$0.73 vs -$0.55 consensus (-32.0% surprise). Revenue of $-257.0K vs $3.0M expected (-108.5%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-32.0%
Revenue trend · last 8Q
—
—
-63%
-57%
-25%
-59%
-70%
-103%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$11.5M
$9.6M
$4.1M
$8.5M
$8.7M
$3.9M
$1.2M
-$257.0K
Margins · last 8Q
Gross
0.0%
Operating
—
Profit
—
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Wells Fargo · May 12, 2026
vs Industry
How MGX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.